Malaria Vaccine R&D and Immunization – Lessons Learned & Considerations for Global Health Impact

Global Vaccine and Immunization Research Forum (GVIRF): Malaria Vaccine R&D and Immunization

The first-generation malaria vaccine RTS,S/ASO1 is an important advance in combatting a difficult pathogen and illustrates critical obstacles facing the vaccine and immunization communities. Using RTS,S/AS01 as a case study, this webinar explored lessons learned and discussed vaccine R&D considerations for malaria and other diseases of global health importance prevalent in resource-limited settings.  

Webinar Topics (see Agenda)

• The RTS,S/AS01 vaccine and lessons learned 
• Future malaria R&D priorities and strategies
• Vaccine development hurdles and challenges
• Implementation and distribution considerations
• Manufacturing and accessibility impediments
• Safety and regulatory concerns 
• Resources and global collaboration

About

The Global Vaccine and Immunization Research Forum (GVIRF) is a global meeting that brings together the entire vaccine and immunization research community and organized by the U.S. National Institute of Allergy and Infectious Diseases (NIAID), the Bill & Melinda Gates Foundation (BMGF), and the World Health Organization (WHO).